Article citationsMore>>

Zhang, L., Jones-O’Connor, M., Awadalla, M., Zlotoff, D.A., Thavendiranathan, P., Groarke, J.D., et al. (2019) Cardiotoxicity of Immune Checkpoint Inhibitors. Current Treatment Options in Cardiovascular Medicine, 21, Article No. 32.
https://doi.org/10.1007/s11936-019-0731-6

has been cited by the following article:

• TITLE: A Clinician’s Approach to Checkpoint Inhibitor Therapy Following Inflammatory Events from Nivolumab

  AUTHORS: Madisen Huscher, Lauren Dwyer, Danica Dodd, Jessup Kenyon

  KEYWORDS: Immune Checkpoint Inhibitor, Myocarditis, Thyroiditis, Treatment of ICI Myocarditis

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.14 No.3, March 21, 2025

  ABSTRACT: With the growing number of monoclonal antibody therapies for oncologic conditions, timely identification and management of their complications are increasingly important for practitioners. This is a case of a 74-year-old female with primary metastatic melanoma who presented with progressive shortness of breath shortly after initiation of nivolumab. The patient’s endomyocardial biopsy was significant for myocyte damage with inflammatory infiltrate and positive PD-1 staining, indicating myocarditis. The hospital course was complicated by cardiac arrest leading to temporary pacemaker placement, atrial fibrillation with rapid ventricular rate, and concomitant thyroiditis. The patient was started on high-dose (1 mg/kg) steroids and mycophenolate for treatment of myocarditis.